

PRESS RELEASE

ZINZINO

Corporate ID no. 556733-1045

FAO: News Editor

Gothenburg 2021-12-03

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2021

Strong sales growth during November; Zinzino group revenue increased with a total of 48%, compared with the previous year.

The revenue in November for Zinzino's sales markets increased by 49% to SEK 140.7 (94.6) million due to strong growth in several regions. Faun Pharma's external sales increased by 28% and amounted to SEK 5.5 (4.3) million. Overall, the Group increased revenues by 48% to SEK 146.2 (98.9) million compared with the previous year.

Accumulated revenue for January – November 2021 increased by 22% to SEK 1221.5 (1004.8) million.

Revenues were distributed as follows:

Regions,MSEK	21-Nov	20-Nov	Change	YTD 2021	YTD 2020	Change
The Nordics	32.0	35.9	-11%	333.7	356.1	-6%
Central Europe	25.2	15.5	63%	205.5	158.4	30%
East Europe	41.3	19.0	117%	304.9	232.5	31%
South & West Europe	15.5	9.3	67%	130.3	76.3	71%
The Baltics	10.3	7.2	43%	68.8	62.2	11%
North America	4.8	3.4	41%	45.3	37.1	22%
Asia-Pacific	11.0	4.3	156%	75.2	28.7	162%
Africa	0.6	0.0		0.6	0.0	
Zinzino	140.7	94.6	49%	1164.3	951.3	22%
Faun Pharma	5.5	4.3	28%	57.2	53.5	7%
Zinzino Group	146.2	98.9	48%	1221.5	1004.8	22%

Countries in regions:

- The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
- Central Europe: Austria, Germany, Switzerland
- East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
- South & West Europe: Cyprus, France, Greece, Italy, Netherlands, Spain, United Kingdom
- The Baltics: Estonia, Latvia, Lithuania
- North America: Canada, USA
- Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
- Africa: South Africa

For more information:

Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:

Marcus Tollbom +46 (0) 70 190 03 12, marcus.tollbom@zinzino.com

Certified Adviser: Erik Penser Bank Aktiebolag, +46 (0) 8 463 83 00, email: certifiedadviser@penser.se

Zinzino AB (publ) is obliged to publish this information in compliance with current EU regulations governing market abuse. The information was provided by the above contact person for publication at 12:00 the 3rd of December 2021.

Zinzino is a global D2C company from Scandinavia specializing in biomarker-based, personalized nutrition. It is a public limited company with its shares listed on Nasdaq First North Premier Growth Market. Their test-based, scientifically proven nutritional supplements are available in over 100 markets across the world.

Zinzino owns the Norwegian research and production units BioActive Foods AS and Faun Pharma AS. The company headquarters is in Gothenburg, Sweden with additional offices in Finland, Latvia, Norway, USA, Australia, Hong Kong, Malaysia, India, Taiwan and South Africa.